The reversal is about more than one damages award. In the stent business, patent rulings can affect bargaining power, product strategy and how much protection device makers can count on after a jury win.
Boston Scientific’s $42 million stent patent verdict was reversed on appeal Thursday, when a federal appeals court in Washington, D.C., threw out the case and handed a win to Johnson & Johnson in a long-running patent fight. The ruling means Boston Scientific gets no immediate benefit from the jury award it had won over coronary stent technology, and this article explains why the reversal matters for Boston Scientific: in medical devices, patents can shape leverage as much as products.
The decision turns a $42M stent patent victory into a legal setback. It also shows why patent litigation in the device industry rarely ends at the jury box, even when the number attached to the verdict looks decisive.
A jury win disappears
According to contemporaneous reports from The Wall Street Journal and Reuters, the appeals court reversed the jury’s decision and threw out Boston Scientific’s case. Reuters quoted the court’s bottom line plainly: We reverse the judgment.
That is the key practical result. Boston Scientific had a $42 million verdict tied to stent patents. After the appeal, that judgment no longer stood.
For Johnson & Johnson, the ruling removed a damages award and the cloud that can come with an infringement finding. For Boston Scientific, it erased a courtroom win that could have supported licensing leverage, future claims or settlement pressure.
The available reports do not show that the ruling immediately changed patient access to any product. The importance sits in the legal and commercial layer behind the devices: who owns protected technology, who may use it and what a rival must pay if it crosses a patent line.
Why stent patents are valuable
Stents are tiny medical devices used to help keep arteries open. They are small, but the business around them has been anything but small. A successful stent platform can represent years of research, regulatory work, physician adoption and manufacturing investment.
That is why patents matter so much in this corner of medical technology. A patent can protect a design feature, delivery system, coating, drug-release method or other technical advance that helps one company’s stent stand apart from another’s.
When a company wins a patent verdict, the dollars are only one part of the prize. The judgment can strengthen its hand in negotiations. It can also make competitors rethink product designs or licensing exposure.
When that verdict is reversed, the effect runs in the opposite direction. The company that won at trial loses leverage, while the accused competitor gains room to argue that the patent claims should not control the market in the way the trial verdict suggested.
The appeals court mattered more
Patent cases often turn on technical questions that juries hear first and appeals courts review later. The appellate stage can focus less on broad impressions and more on legal standards, claim language and whether the trial court allowed the case to reach the jury on the right footing.
That is why a jury verdict, even a multimillion-dollar one, can be unstable. The first decision may set the headline number. The appeal can decide whether that number survives.
Here, the federal appeals court in Washington, D.C., did not merely reduce the damages award. The reports say it threw out Boston Scientific’s case. That distinction matters because it suggests the problem was not simply how much money the jury awarded, but whether the judgment could stand at all.
For investors and industry watchers, that makes the ruling more consequential than a routine damages adjustment. It changes the legal posture of the dispute and weakens the immediate value of the earlier victory.
Boston Scientific knows this cycle
Boston Scientific has been on both sides of major stent-patent rulings. That history gives the reversal context: device makers can win one patent battle, lose another and keep fighting over different products, patents and markets for years.
The New York Times reported in 2004 that Boston Scientific won a ruling from the European Patent Office involving stent patents linked to Medinol Ltd. That decision invalidated a Medinol patent and allowed Boston Scientific to resume sales of Express and Taxus brand stents in the Netherlands, according to the report.
A company release from 2005 pointed to another win, saying the Court of Appeals for the Federal Circuit upheld trial court decisions that Boston Scientific’s TAXUS Express, Express and NIR stents did not infringe four Medtronic stent patents. Boston Scientific’s then-chief operating officer Paul LaViolette said at the time that the decision reaffirmed the company’s drug-eluting stent technology.
Those earlier examples do not change the Johnson & Johnson result. They do show the broader pattern: stent patents are a recurring battleground, and appellate courts can swing outcomes sharply in either direction.
What the reversal changes
The most immediate change is obvious. Boston Scientific lost the benefit of a $42 million judgment, and Johnson & Johnson avoided that liability in the case as reported.
The less obvious change is strategic. A reversed verdict can affect how aggressively a company asserts related patents, how rivals assess litigation risk and how both sides approach any future settlement discussions.
There are competing views of what rulings like this mean for the device market. Patent holders argue that strong protection rewards expensive innovation and keeps companies investing in better technology. Competitors often argue that overly broad or weak patents can fence off ideas that should remain available for design-around competition.
Courts sit between those positions. A reversal does not necessarily mean the underlying technology lacked value. It means the legal claim, as presented and judged through the appeals process, did not support the verdict.
What remains unresolved
Reuters reported that Boston Scientific did not immediately say whether it would appeal further and said the company was considering its options. That leaves the next step less clear than the headline result.
In patent litigation, possible next moves can include asking the appeals court to rehear the matter or seeking review by the Supreme Court, though higher review is not guaranteed. Companies can also keep fighting separate patent disputes even after one case ends.
What is clear is that the $42 million verdict is no longer a bankable win for Boston Scientific. The appeals court’s decision shifts the advantage to Johnson & Johnson in this dispute and underscores a hard rule of medical-device litigation: a verdict is powerful only if it survives appeal.
For Boston Scientific, the reversal is a legal loss. For the broader stent market, it is another reminder that patents are not just paperwork behind medical devices. They are part of the competitive machinery that determines who can sell, who can collect and how far innovation claims can reach.
Leave a Reply